Search Results - "Hargarter, L"

Optimising treatment to achieve long-term recovery by Hargarter, L

Get full text

C.08.02 Providing optimal treatment by Hargarter, L

Get full text

Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia by Hargarter, L, Bergmans, P, Cherubin, P, Keim, S, Conca, A, Serrano-Blanco, A, Bitter, I, Bilanakis, N, Schreiner, A

“…To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral…”
Get more information

Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period - a retrospective observational study by Hargarter, L, Bergmans, P, Cherubin, P, Schreiner, A

“…Introduction Little is known about patient characteristics and rehospitalization in newly diagnosed patients with schizophrenia treated with long-acting…”
Get full text

Clinical and functional response to paliperidone palmitate in early schizophrenia–A retrospective observational study in newly diagnosed patients treated over a 12-month period by Hargarter, L, Bergmans, P, Cherubin, P, Schreiner, A

“…Introduction Data on clinical outcomes with long-acting antipsychotic treatment in young, newly diagnosed patients with schizophrenia is sparse. Objectives To…”
Get full text

Paliperidone Palmitate – Effect On Negative, Depression/anxiety, Patient Functioning and Extrapyramidal Symptoms in Non-acute Schizophrenia Patients Previously Unsuccessfully Treated with Oral Aripiprazole by Schreiner, A, Bergmans, P, Cherubin, P, Hargarter, L

“…Introduction To explore the effect of flexibly dosed paliperidone palmitate (PP) on negative, depression/anxiety, patient functioning and extrapyramidal…”
Get full text

Tolerability, Safety and Treatment Response of Flexibly-dosed Paliperidone Palmitate in Patients Hospitalized for an Exacerbation of Schizophrenia by Hargarter, L, Lahaye, M, Cherubin, P, Schreiner, A

“…Objective To explore tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate (PP) in adult patients hospitalized for an…”
Get full text

Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations) by Savitz, A, Xu, H, Gopal, S, Nuamah, I, Hough, D, Hargarter, L

Get full text

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics by Schreiner, A, Bergmans, P, Cherubin, P, Keim, S, Llorca, P-M, Cosar, B, Petralia, A, Corrivetti, G, Hargarter, L

“…PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n =…”
Get full text

Schizophrenia through the carers' eyes: results of a European cross-sectional survey by Svettini, A., Johnson, B., Magro, C., Saunders, J., Jones, K., Silk, S., Hargarter, L., Schreiner, A.

“…Accessible summary Schizophrenia is a serious mental disorder affecting approximately 29 million people worldwide. The ideal treatment and care of patients…”
Get full text

Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia by Savitz, A, Xu, H, Gopal, S, Nuamah, I, Ravenstijn, P, Hough, D, Hargarter, L, Fleischhacker, W.W

Get full text

1100 – Safety, tolerability and treatment response with flexible doses of paliperidone palmitate in patients with an acute exacerbation of schizophrenia by Schreiner, A, Hargarter, L, Bergmans, P, Cherubin, P

“…Objective To explore tolerability, safety and treatment response with flexible doses of paliperidone palmitate in adult patients with an acute episode of…”
Get full text

1096 – Safety, tolerability and treatment response with flexible doses of paliperidone palmitate in non-acute patients with schizophrenia by Schreiner, A, Hargarter, L, Bergmans, P, Cherubin, P

“…Objective To explore tolerability, safety and treatment response of flexible doses of paliperidone palmitate in adult non-acute patients with schizophrenia…”
Get full text

Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR) by Schreiner, A., Hargarter, L., Hitschfield, K., Lee, J.I., Lenskaya, I., Sulaiman, A.H., Diels, J.

“…Abstract Objective: To document prescribing patterns in clinical practice and assess long-term outcomes related to initiation of paliperidone ER and other oral…”
Get full text

EPA-1552 - Flexibly dosed paliperidone palmitate in non-acute but symptomatic patients with schizophrenia previously unsuccessfully treated with long-acting injectable risperidone by Schreiner, A, Bergmans, P, Llorca, P.M, Corrivetti, G, Cosar, B, Cherubin, P, Hargarter, L

“…Introduction To explore tolerability, safety and treatment response of flexibly dosed paliperidone palmitate (PP) in adult non-acute but symptomatic patients…”
Get full text

EPA-1553 - Flexibly dosed paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with conventional depot antipsychotics by Schreiner, A, Hargarter, L, Llorca, P.M, Cosar, B, Petralia, A, Bergmans, P, Cherubin, P

“…Introduction To explore tolerability, safety and treatment response of flexibly dosed paliperidone palmitate (PP) in adult non-acute patients with…”
Get full text

P.3.b.018 Posthoc analysis of patient relapse rates when switching from risperidone or other antipsychotics to paliperidone palmitate by Schreiner, A, Gopal, S, Thiagarajah, S, Busch, M, Alphs, L, Coppola, D, Hargarter, L, Vidal, J.A. Buron, Remmerie, B, Samtani, M.N, Zhang, F, Savitz, A, Hough, D

Get full text

EPA-1548 - Flexibly dosed paliperidone palmitate in non-acute patients with schizophrenia switched from previously unsuccessful monotherapy with oral atypical antipsychotics by Hargarter, L, Bergmans, P, Cherubin, P, Rancans, E, Bez, Y, Parellada, E, Carpiniello, B, Vidailhet, P, Schreiner, A

“…Introduction To explore tolerability, safety and treatment response of flexibly dosed paliperidone palmitate (PP) in adult non-acute schizophrenia patients…”
Get full text

EPA-1551 - Paliperidone palmitate – impact on negative, disorganized and depressive symptoms, subjective well-being and patient satisfaction in patients with schizophrenia previously unsuccessfully treated with oral antipsychotics by Schreiner, A, Hargarter, L, Bergmans, P, Cherubin, P, Rancans, E, Bez, Y, Parellada, E, Carpiniello, B, Vidailhet, P

“…Introduction Negative, disorganized and depressive symptoms are among the major unmet needs in the treatment of patients with schizophrenia. The objective of…”
Get full text

EPA-1545 - Functional outcomes with once-monthly paliperidone palmitate in acute and in non-acute patients with schizophrenia previously unsuccessfully treated with oral antipsychotics by Hargarter, L, Bergmans, P, Cherubin, P, Björner, A, Knegtering, R, Parellada, E, Carpiniello, B, Vidailhet, P, Mertens, C, Schreiner, A

“…Introduction Effective antipsychotic treatment of schizophrenia should, beyond symptom control, translate into meaningful functional improvements. This study…”
Get full text